Cellectis Financial Overview and Future Directions
NEW YORK, May 12, 2025 -- Cellectis, a clinical-stage biotechnology firm focused on gene editing and cell therapies, recently announced their financial results for the first quarter of 2025. The company, listed on both Euronext Growth (ALCLS) and Nasdaq (CLLS), is at the forefront of developing life-saving therapies designed to combat various medical conditions, particularly cancer.
"We are making measurable progress in our solely-owned clinical studies as well as in the three collaborative initiatives we have established with AstraZeneca. Our primary focus remains on advancing these pivotal programs, and we are eager to share results in the coming months," stated André Choulika, Ph.D., Chief Executive Officer of Cellectis.
Key Highlights from Cellectis' Pipeline
Innovative Gene-Editing Projects
One of the standout projects from Cellectis is their BALLI-01 study, which evaluates lasme-cel (UCART22) for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). As of mid-April 2025, the World Health Organization (WHO) designated lasmecabtagene timgedleucel as the recommended international non-proprietary name for UCART22. Anticipated to provide a Phase 1 dataset and late-stage development strategy, updates for lasme-cel are expected by the third quarter of 2025.
Eti-cel Study Progress
Additionally, the NATHALI-01 study assessing eti-cel (UCART20x22) in relapsed or refractory B-cell non-Hodgkin lymphoma is currently in progress. The WHO has similarly recommended the name etivelcabtagene erigedleucel for UCART20x22. Cellectis continues to prioritize patient enrollment and projects an important Phase 1 readout for eti-cel in late 2025.
Research and Development Collaborations
Cellectis has also engaged in a strategic partnership with AstraZeneca, focusing on several innovative programs. These include one allogeneic CAR T treatment targeting hematological malignancies, another for solid tumors, and a revolutionary in vivo gene therapy addressing genetic disorders. This multi-faceted collaborative approach underlines Cellectis' commitment to leveraging partnerships in advancing cell and gene therapies.
Financial Insights and Future Outlook
As of March 31, 2025, Cellectis reported a cash position of $246 million, a figure that assures stakeholders of operational stability through 2027. This financial cushion primarily supports the ongoing development and manufacturing expenses for UCART22, UCART20x22, and forthcoming product candidates.
In the first quarter of 2025, Cellectis generated $12.0 million in consolidated revenues, substantially higher than the $6.5 million reported the previous year, thanks in part to $5.9 million recognized under their collaboration with AstraZeneca. Research and development expenses totaled $21.9 million, highlighting the significant investments being made in advancing their therapies.
Commitment to Advanced Gene Technologies
Cellectis is dedicated to pushing the boundaries of gene editing technology, with a focus on non-viral methods. The company will showcase novel gene editing techniques at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting, aimed at enhancing cellular and gene therapies.
Cellectis is notably positioned as a complete gene editing company, controlling the process from development to manufacturing, and thereby ensuring the quality and effectiveness of their therapies. The company has facilities in both Paris and Raleigh, NC, allowing them to maintain high standards throughout the value chain.
Frequently Asked Questions
What does Cellectis specialize in?
Cellectis specializes in gene editing and developing cell and gene therapies, particularly using CAR T technologies to treat cancer.
When are the expected results for the UCART22 program?
The Phase 1 dataset and development strategy for the lasme-cel program are expected to be presented in the third quarter of 2025.
How much cash does Cellectis have for operations?
As of March 31, 2025, Cellectis reported a cash position of $246 million, which is projected to be sufficient for operations through 2027.
What financial performance did Cellectis report in Q1 2025?
Cellectis achieved $12.0 million in revenues during the first quarter of 2025, compared to $6.5 million in the same quarter of the previous year.
Where can I find more information about Cellectis?
More information can be found on their official website at www.cellectis.com.
